Antibody Expression Services
Antibody expression platforms from Absolute Antibody rapidly produce high-quality, animal-free recombinant antibodies at milligram-to-gram scale in HEK or CHO cells.
Receive your quote directly from the manufacturer.
The serum-free mammalian transient expression system offers a faster, more affordable alternative to stable cell line generation, and Absolute Antibody use it to manufacture recombinant antibodies in any species, isotype or format with high purity and low endotoxin levels.
Depending on your antibody expression needs, Absolute Antibody are a reliable outsourcing solution for antibody production, or a true consultative partner for developing the best possible engineered antibody. All production occurs at an ISO 9001:2015-certified manufacturing facility, which enables high-throughput capacity and the ability to scale up to multi-gram quantities within weeks.
Bispecific ADCs targeting the cancer, not the patient
Tuesday, July 28 at 15:00 BST | 16:00 CEST | 10:00 EDT | 07:00 PDT
Bispecific antibody-drug conjugates (ADCs) represent an emerging frontier in targeted cancer therapy, combining the precision of antibody-based targeting with the potency of cytotoxic payloads. By recognizing two distinct tumor-associated markers rather than one, bispecific ADCs can improve tumor selectivity, helping to distinguish cancer cells from healthy tissue and potentially reducing off-target effects. As the field advances, researchers are exploring innovative approaches to address longstanding challenges in efficacy, safety, and patient outcomes, making bispecific ADCs a rapidly growing area of interest in oncology research and drug development.
This SelectScience webinar introduces BiVictriX Therapeutics and its role as an early pioneer in bispecific, logic gated, ADCs. It will cover how ADCs are reshaping targeted cancer therapy and why bispecific targeting offers a route to improved tumor selectivity and reduced off-tumor toxicity. The presentation will also explore the key steps to take when designing a bispecific ADC, including target selection, antibody format, linker strategy, and payload choice, and how these decisions influence efficacy, safety, and clinical potential.
Antibody expertise and bespoke reagents elevate life sciences research
See how Life Science Group and Absolute Antibody partner to deliver a flexible antibody offering for future-focused life sciences research
